Sleep Quality and Quality of Life in Coronavirus 19 Disease ( COVID 19) Patients Read more about Sleep Quality and Quality of Life in Coronavirus 19 Disease ( COVID 19) Patients
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older Read more about Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study Read more about Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study
COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients Read more about COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients
Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19 Read more about Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19
Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study . Read more about Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study .
Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older Read more about Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older
Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 Read more about Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19
Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection Read more about Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over Read more about Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over
